oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2020 ( 2 )

2019 ( 204 )

2018 ( 320 )

2017 ( 296 )

Custom range...

Search Results: 1 - 10 of 297595 matches for " Beier J "
All listed articles are free for downloading (OA Articles)
Page 1 /297595
Display every page Item
Long-acting -adrenoceptor agonists in the management of COPD: focus on indacaterol
Beier J, Beeh KM
International Journal of Chronic Obstructive Pulmonary Disease , 2011, DOI: http://dx.doi.org/10.2147/COPD.S7371
Abstract: ng-acting -adrenoceptor agonists in the management of COPD: focus on indacaterol Review (6892) Total Article Views Authors: Beier J, Beeh KM Published Date April 2011 Volume 2011:6 Pages 237 - 243 DOI: http://dx.doi.org/10.2147/COPD.S7371 Jutta Beier, Kai M Beeh insaf Respiratory Research Institute, Wiesbaden, Germany Abstract: Bronchodilators are the cornerstone of severe chronic obstructive pulmonary disease (COPD) treatment to improve airflow, symptoms, exercise tolerance, and exacerbations. There is convincing evidence that regular treatment with long-acting bronchodilators is more effective and convenient than treatment with short-acting bronchodilators. Long-acting -2-agonists include the twice-daily drugs formoterol and salmeterol and, more recently, once-daily indacaterol. Studies with head-to-head comparisons of long-acting bronchodilators are scant, but novel data from controlled trials with the once-daily (2)-agonist indacaterol indicate superior bronchodilation and clinical efficacy of indacaterol at recommended doses over twice-daily long-acting (2)-agonists, and at least equipotent bronchodilation compared with once-daily tiotropium. The recent therapeutic developments in COPD underscore a shift from short-acting bronchodilators with multiple dosings per day to reduced dosing frequency and prolonged duration of action, including once-daily treatment, with more consistent effects on various clinical outcomes. This review summarizes relevant clinical data for twice-daily -2-agonists in COPD, and further focuses on novel data for once-daily indacaterol, including head-to-head comparison trials.
Desperately Seeking Stable 50-Year-Old Landscapes with Patches and Long, Wide Corridors
Paul Beier,Andrew J. Gregory
PLOS Biology , 2012, DOI: 10.1371/journal.pbio.1001253
Abstract:
Two researchers desperately seek stable 50‐year‐old corridors for study on conservation corridor efficacy
Paul Beier,Andrew J. Gregory
Frontiers of Biogeography , 2011,
Abstract:
Desperately Seeking Stable 50-Year-Old Landscapes with Patches and Long, Wide Corridors
Paul Beier ,Andrew J. Gregory
PLOS Biology , 2012, DOI: 10.1371/journal.pbio.1001253
Abstract:
2001: a mouse genome odyssey
David R Beier, Bruce J Herron
Genome Biology , 2002, DOI: 10.1186/gb-2002-3-2-reports4005
Abstract: In a year notable for the completion of a draft human genome sequence, it was appropriate that a major topic at the 15th International Mouse Genome Conference was a discussion of the status of the mouse genome project. Details of the public-domain effort were presented by John McPherson (Washington University, St Louis, USA), Kerstin Lindblad-Toh (Whitehead Institute, Cambridge, USA), Shaying Zhao (The Institute for Genomic Research, Rockville, USA), Anne-Marie Mallon (Medical Research Council Mouse Genome Centre and Mammalian Genetics Unit (MRC MGU/MGC), Harwell, UK), and Jim Thomas (National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, USA). The approach being taken combines sequencing of bacterial artificial chromosomes (BACs) - this was the main method for sequencing the human genome - and whole-genome shotgun sequencing, which is advocated by investigators at Celera Genomics. A fingerprinted physical map of 300,000 BAC clones has been generated and aligned to the mouse radiation-hybrid map using sequence-tagged sites (STSs) derived from microsatellite sequences and expressed sequence tags (ESTs). The precise position of the BACs on the map is being refined with the help of the sequences of the ends of many of the BACs. Nearly threefold (3x) coverage of the genome using shotgun sequence has been completed and deposited in public domain databases.One aim of the public mouse genome-sequencing effort is to generate shotgun-sequence reads from different mouse strains, in order to identify single-nucleotide polymorphisms (SNPs). (As plans for this component are in development, we propose that the validation and characterization of SNPs in a large number of commonly used inbred strains is as important as SNP discovery itself, and urge that appropriate resources be devoted to it). An important part of genomics is the informatics required for data management and analysis; programs for organizing and annotating mouse genome sequence in
Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients
Beier J,van Noord J,Deans A,Brooks J
International Journal of COPD , 2012,
Abstract: Jutta Beier1, Jan van Noord2, Amanda Deans3, Jean Brooks3, Claire Maden3, Suus Baggen4, Rashmi Mehta5, Anthony Cahn31INSAF Respiratory Research Institute, Germany; 2Atrium Medisch Centrum, The Netherlands; 3GlaxoSmithKline, Stockley Park, UK; 4GlaxoSmithKline, Zeist, The Netherlands; 5GlaxoSmithKline, RTP, NC, USABackground: GSK233705 is an inhaled, long-acting muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). This study was performed to see if the addition of GSK233705 to salmeterol would provide greater bronchodilation than salmeterol or tiotropium alone in COPD.Methods: In an incomplete-block, three-period, crossover design, dually responsive patients received three of the following five treatments: GSK233705 20 μg plus salmeterol 50 μg twice-daily; GSK233705 50 μg plus salmeterol 50 μg twice-daily; salmeterol 50 μg or placebo, each twice-daily; and tiotropium 18 μg or placebo once-daily for 7 days. Each treatment period was separated by a 14-day washout. The primary efficacy endpoint was morning (trough) forced expiratory volume in 1 second (FEV1) on Day 8, following 7 days of treatment. Secondary endpoints included pulmonary function, plethysmography, pharmacokinetics of GSK233705 and salmeterol, adverse events (AEs), electrocardiograms (ECGs), vital signs, and laboratory parameters.Results: A total of 47 patients were randomized. The mean % predicted normal postbronchodilator FEV1 was 55% at screening. Compared with placebo (n = 24), the adjusted mean change from baseline in trough FEV1 on Day 8 was 215 mL higher with GSK233705 20 μg + salmeterol (n = 23) and 203 mL higher with GSK233705 50 μg + salmeterol (n = 27), whereas with salmeterol (n = 27) and tiotropium (n = 28) the changes were 101 mL and 118 mL higher, respectively. The primary efficacy results were supported by the results from the other secondary lung function assessments. AEs were reported by similar proportions of patients across the treatment groups, with headache the most frequently reported treatment-related AE reported by one subject receiving each of GSK233705 20 μg + salmeterol, tiotropium, and placebo. No significant differences were seen in vital signs, ECGs, or laboratory parameters between the groups.Conclusion: The addition of GSK233705 to salmeterol in partially reversible COPD patients resulted in greater bronchodilation than salmeterol or tiotropium alone and was well tolerated.Keywords: COPD, bronchodilation, dual therapy, LAMA, LABA
Raman Microspectroscopy for Species Identification andMapping within Bacterial Biofilms
Brooke D Beier, Robert G Quivey, Andrew J Berger
AMB Express , 2012, DOI: 10.1186/2191-0855-2-35
Abstract:
The PI3K pathway regulates endochondral bone growth through control of hypertrophic chondrocyte differentiation
Veronica Ulici, Katie D Hoenselaar, J Ryan Gillespie, Frank Beier
BMC Developmental Biology , 2008, DOI: 10.1186/1471-213x-8-40
Abstract: Employing an organ culture system of embryonic mouse tibiae and LY294002, a pharmacological inhibitor of PI3K, we show that inhibition of the pathway results in significant growth reduction, demonstrating that PI3K is required for normal endochondral bone growth in vitro. PI3K inhibition reduces the length of the proliferating and particularly of the hypertrophic zone. Studies with organ cultures and primary chondrocytes in micromass culture show delayed hypertrophic differentiation of chondrocytes and increased apoptosis in the presence of LY294002. Surprisingly, PI3K inhibition had no strong effect on IGF1-induced bone growth, but partially blocked the anabolic effects of C-type natriuretic peptide.Our data demonstrate an essential role of PI3K signaling in chondrocyte differentiation and as a consequence of this, in the endochondral bone growth process.Bone formation occurs through two different mechanisms: endochondral and intramembranous ossification. Longitudinal growth of the axial and appendicular skeleton is a result of endochondral ossification (EO) that is controlled by the cartilage growth plate [1]. EO involves the aggregation of mesenchymal cells to form cartilaginous nodules [2]. A subset of the cells in these nodules matures further into growth plate chondrocytes.During endochondral bone development in the limb, growth plate chondrocytes undergo well-ordered and controlled phases of cell proliferation, maturation, and apoptosis [3]. The growth plate can be divided into three main chondrocyte subpopulations: the resting, proliferating and hypertrophic chondrocytes. These populations are arranged in distinct zones that are distinguishable by morphological criteria, but are also characterized by specific molecular markers. The proliferation and/or differentiation of these subpopulations are controlled by a complex network of regulatory molecules [4]. Proliferative chondrocytes synthesize type II collagen and form characteristic columns; they then exit t
Effects of nitrogen deposition and climate change on nitrogen runoff at Norwegian boreal forest catchments: the MERLIN model applied to Risdalsheia (RAIN and CLIMEX projects)
R. F. Wright,C. Beier,B. J. Cosby
Hydrology and Earth System Sciences (HESS) & Discussions (HESSD) , 1998,
Abstract: The catchment scale-experiments of the RAIN and CLIMEX projects conducted on boreal forest ecosystems at Risdalsheia, southernmost Norway, provide a unique set of data on the flux of nitrogen (N) in runoff following changes in N deposition, carbon dioxide (CO2) level and temperature. MERLIN (Model of Ecosystem Retention and Loss of Inorganic Nitrogen), a recently-developed model that focuses on N leaching, provides a means by which these data can be placed into a quantitative framework. The features of the N flux in runoff at Risdalsheia to be explained include (1) leaching of about 30-50 mmol m-2 yr-1 (30-40% of N deposition) during the period 1985-1997 at reference catchments, (2) rapid and dramatic reduction in N leaching following experimental reduction in N deposition in 1985 at KIM catchment, (3) increased flux of about 5 mmol m-2 yr-1 following onset of 3-5°C warming and increased CO2 in 1995 at KIM catchment, and (4) increased flux of about 12 mmol m-2 yr-1 following 3-5°C warming of soil in 1995 at EGIL catchment. One set of calibrated model parameters is sufficient to simulate the changes in N runoff at both experimental catchments for both of the manipulations. The model support the conceptual picture of the soil as the major sink for N inputs from deposition with N accumulating in both the forest floor (labile organic matter LOM) and the bulk soil (refractory organic matter ROM). As the molar carbon/nitrogen (C/N) ratio of LOM decreases to below 23, progressively less N is immobilised and more goes to runoff. The model also supports the conceptual picture of increased rate of decomposition of old soil organic matter in response to higher temperature. An increase of 5% is sufficient to produce the 5-12 mmol m-2 yr-1 increase in N flux in runoff observed at the 2 experimental catchments. The MERLIN simulations are consistent with measurements of increase in net mineralisation rates (per catchment area by 70 mmol m-2 yr-1) and N contents in foliage in treated and reference areas before and after onset of treatment. Runoff provides a very sensitive indicator of changes in N cycling within the ecosystem. Small changes in key processes such as N mineralisation give rise to large relative changes in N flux. Uncertainties in measurements are generally much larger than changes indicated by the model calibration.
"Lessons learned" nach 462 Harnr hrenstriktur-Rekonstruktionen mit Mundschleimhaut
Dobkowicz L,Pandey A,Beier J,Keller H
Journal für Urologie und Urogyn?kologie , 2010,
Abstract: Die Rekonstruktion einer langstreckigen Rezidivharnr hrenstriktur erfordert einen Gewebetransfer mittels eines vaskularisierten Lappens oder eines freien Transplantates. Die Verfahrensweisen bezüglich des operativen und perioperativen Managements werden abgeleitet aus Empfehlungen und Ergebnissen der Literatur, die meist auf kleinen Fallzahlen basieren und nicht immer evidenzbasiert sind. Ziel unserer Studie war die überprüfung der Literaturempfehlungen und -ergebnisse anhand unseres eigenen Patientenklientels. Von 04/1994 bis 08/2009 evaluierten wir prospektiv 462 konsekutiv mittels Mundschleimhauttransplantat durchgeführte Strikturrekonstruktionen mit einem standardisierten Fragebogen. Erfasst wurden der Harnstrahl und die Restharnmenge alle 3 Monate in den ersten beiden postoperativen Jahren, dann halbj hrlich lebenslang. Das mittlere Follow-up lag bei 54 Monaten (1 153), 135 Patienten hatten ein Follow-up von zumindest 60 Monaten ( 5 Jahre). Die Rezidivrate lag in unserem Gesamtkollektiv bei 5,8 % (27/462). Die Rezidivrate der endoskopisch voroperierten Patienten unterscheidet sich nicht signifikant von der der offen voroperierten (5,7 %/6,4 % [21/368; 6/ 94]) p = 0,49. Die 3x voroperierten Patienten haben keine h here Rezidivrate als die h ufiger ( 3x) voroperierten Patienten (3,6 %/7,9 % [7/193; 20/ 254]) p = 0,47. Die Strikturl nge ( 10/ 10 cm) zeigt im Vergleich keine h here Rezidivrate (5,4 %/7,0 % [15/ 278; 12/171]) p = 0,68. Ebenfalls keinen signifikanten Unterschied konnten wir in der Rezidivrate bzgl. der unterschiedlichen Lokalisation der Rezidivharnr hrenstriktur (penil bulb r & bulbomembran s gesamte Harnr hre) finden, (1/60 penil, 7/113 penobulb r, 10/187 bulb r, 1/13 bulbomembran s, 8/89 gesamte Harnr hre) p = 0,7; 0,21; 0,47. Eine Wartezeit von mind. 3 Monaten nach vorausgegangener endoskopischer Operation vor offener Harnr hrenrekonstruktion ist nicht erforderlich. Die Anzahl vorausgegangener Operationen, die intraoperative Strikturl nge und die Strikturlokalisation haben keinen Einfluss auf ein eventuelles Harnr hrenstrikturrezidiv. Literaturempfehlungen sollten aufgrund dieser Ergebnisse kritisch auf ihre Evidenz geprüft werden.
Page 1 /297595
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.